Winlevi Cream
NDC 47335-994
Product Information
Winlevi (clascoterone) is a NDA-approved product labeled by Sun Pharmaceutical Industries, Inc.. This medication is typically used as a androgen receptor antagonists [moa]. It is supplied as a white cream for topical administration. This product entry covers the primary NDC 47335-994 and 2 associated package configurations. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
Clinical Specifications
Labeler & Regulatory Data
Marketing Timeline
Product Characteristics
Code Structure Chart
Product Details
What is NDC 47335-994?
What are the uses of this product?
What are Active Ingredients of this product?
- CLASCOTERONE 1 g/100g - a topical and peripherally selective androgen antagonist
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- CLASCOTERONE (UNII: XN7MM8XG2M)
- CLASCOTERONE (UNII: XN7MM8XG2M) (Active Moiety)
Which are the Inactive Ingredients associated UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- PROPYLENE GLYCOL (UNII: 6DC9Q167V3)
- WATER (UNII: 059QF0KO0R)
- GLYCERYL MONO AND DICAPRYLOCAPRATE (UNII: U72Q2I8C85)
- MINERAL OIL (UNII: T5L8T28FGP)
- CETYL ALCOHOL (UNII: 936JST6JCN)
- POLYSORBATE 80 (UNII: 6OZP39ZG8H)
- EDETATE DISODIUM (UNII: 7FLD91C86K)
- .ALPHA.-TOCOPHEROL (UNII: H4N855PNZ1)
What is the NDC to RxNorm Crosswalk for this product?
- RxCUI: 2474344 - clascoterone 1 % Topical Cream
- RxCUI: 2474344 - clascoterone 10 MG/ML Topical Cream
- RxCUI: 2474349 - Winlevi 1 % Topical Cream
- RxCUI: 2474349 - clascoterone 10 MG/ML Topical Cream [Winlevi]
- RxCUI: 2474349 - Winlevi 10 MG/ML Topical Cream
Which are the Pharmacologic Classes of this product?
* Please review the full disclaimer at the bottom of this page.